Ora Biomedical and the Rapamycin Longevity Lab have successfully secured $50,000 to kick off their initiative focused on analyzing 601 mTOR inhibitors in roundworms.

Keith Comito, Board President of the Lifespan Research Institute, underscored the significance of rigorous scientific methods in enhancing longevity interventions and thanked contributors for their support in the screening process.

Mitchell Lee, CEO of Ora Biomedical, has emphasized the urgent need for improved interventions targeting aging and expressed gratitude to the donors who have supported this initiative.

Krister Kauppi, the project leader at Rapamycin Longevity Lab, highlighted the critical importance of developing a large, publicly available dataset to advance the field of longevity research.

The next phase of this research will utilize WormBot-AI technology for high-throughput screening of 301 mTOR inhibitors, with the goal of discovering new compounds that may surpass the effectiveness of rapamycin.

To complete the dataset necessary for advanced longevity research, an additional $40,000 is needed to fund the remaining 300 mTOR inhibitors.

Organizations and individuals interested in supporting this vital research are encouraged to reach out to Krister Kauppi at the Rapamycin Longevity Lab.